Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
22.16
-0.28 (-1.25%)
At close: Feb 13, 2026, 4:00 PM EST
22.54
+0.38 (1.71%)
After-hours: Feb 13, 2026, 7:38 PM EST
Immunome Market Cap
Immunome has a market cap or net worth of $2.44 billion as of February 13, 2026. Its market cap has increased by 184.49% in one year.
Market Cap
2.44B
Enterprise Value
2.18B
1-Year Change
184.49%
Ranking
Category
Stock Price
$22.16
Market Cap Chart
Since the IPO on October 2, 2020, Immunome's market cap has increased from $111.39M to $2.44B, an increase of 2,094.93%. That is a compound annual growth rate of 77.75%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 2.44B | 3.17% |
| Dec 31, 2025 | 2.37B | 257.53% |
| Dec 31, 2024 | 662.87M | 44.98% |
| Dec 29, 2023 | 457.21M | 1,605.70% |
| Dec 30, 2022 | 26.80M | -82.91% |
| Dec 31, 2021 | 156.82M | 53.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 2, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Viridian Therapeutics | 2.66B |
| IDEAYA Biosciences | 2.65B |
| Tarsus Pharmaceuticals | 2.58B |
| Dyne Therapeutics | 2.56B |
| Travere Therapeutics | 2.49B |
| Adaptive Biotechnologies | 2.47B |
| Arcus Biosciences | 2.34B |
| Wave Life Sciences | 2.32B |